Tempest Therapeutics Inc.

NASDAQ: TPST · Real-Time Price · USD
10.58
1.10 (11.60%)
At close: Aug 15, 2025, 3:59 PM
10.72
1.32%
After-hours: Aug 15, 2025, 07:28 PM EDT

Tempest Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
486K 486K 486K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
476K 409K 341K 98K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
10K 77K 145K -183K -595K -1.09M -1.65M -2.1M -2.04M -1.95M -1.81M -1.68M -1.66M -1.47M -1.22M -815K -393K -176K
Operating Income
-43.37M -44.99M -42.02M -35.62M -31.66M -29.55M -29.16M -30.58M -32.76M -34.06M -34.64M -33.04M -32.01M -30.02M -26.99M -23.97M -21.67M -20.12M
Interest Income
1.05M 1.3M 1.5M 1.53M 1.21M 1.07M 921K 859K 859K 685K 399K 73K 136K 69K 69K 72K 12K 18K
Pretax Income
-43.1M -44.8M -41.84M -35.52M -31.75M -29.76M -29.49M -31.11M -33.27M -34.85M -35.71M -34.38M -33.55M -31.44M -28.3M -24.84M -22.16M -20.34M
Net Income
-43.1M -44.8M -41.84M -35.52M -31.75M -29.76M -29.49M -31.11M -33.44M -35.03M -35.88M -34.56M -33.55M -31.44M -28.3M -24.84M -22.16M -20.34M
Selling & General & Admin
13.57M 13.22M 13.55M 13.7M 13.08M 12.39M 11.66M 11.47M 11.89M 11.96M 12.11M 11.6M 11.9M 11.34M 9.82M 8.52M 6.58M 5.17M
Research & Development
29.8M 31.76M 28.48M 21.92M 18.58M 17.16M 17.5M 19.11M 20.86M 22.1M 22.53M 21.45M 20.11M 18.68M 17.17M 15.45M 15.09M 14.95M
Other Expenses
-67K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
43.3M 44.99M 41.94M 35.53M 31.57M 29.46M 29.16M 30.58M 32.76M 34.06M 34.64M 33.04M 32.01M 30.02M 26.99M 23.97M 21.67M 20.12M
Interest Expense
783K 1.11M 1.32M 1.45M 1.49M 1.47M 1.45M 1.5M 1.52M 1.63M 1.62M 1.63M 1.68M 1.49M 1.39M 944K 507K 231K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
43.37M 44.99M 42.02M 35.62M 31.66M 29.55M 29.16M 30.58M 32.76M 34.06M 34.64M 33.04M 32.01M 30.02M 26.99M 23.97M 21.67M 20.12M
Income Tax Expense
n/a n/a 44.72K 44.72K 44.72K 44.72K n/a n/a 176K 176K 176K 176K 63K 66K 66K 66K 3K n/a
Shares Outstanding (Basic)
3.8M 3.44M 27.9M 25.81M 22.55M 22.23M 21.52M 14.12M 14.1M 13.76M 10.52M 13.64M 11.57M 7.17M 6.72M 6.72M 925.43K 6.64M
Shares Outstanding (Diluted)
3.8M 3.44M 27.9M 25.81M 22.55M 22.23M 21.52M 14.12M 14.1M 13.76M 10.52M 13.64M 11.57M 7.17M 6.72M 6.72M 925.43K 6.64M
EPS (Basic)
-6.14 -4.49 -1.69 -1.54 -1.61 -1.73 -1.95 -2.55 -2.73 -2.98 -3.58 -3.79 -4.34 -11.18 -10.81 -14.32 -13.93 -7.09
EPS (Diluted)
-6.14 -4.49 -1.69 -1.54 -1.61 -1.73 -1.95 -2.55 -2.73 -2.98 -3.58 -3.79 -4.34 -11.18 -10.81 -14.32 -13.93 -7.09
EBITDA
-42.24M -43.32M -40.14M -33.65M -29.42M -27.11M -26.39M -27.5M -29.71M -31.27M -32.59M -31.69M -30.83M -29.1M -26.1M -23.1M -21.21M -19.8M
EBIT
-42.32M -43.69M -40.53M -34.07M -30.26M -28.29M -28.04M -29.6M -31.75M -33.23M -34.09M -32.86M -31.98M -30.05M -27.02M -23.91M -21.67M -20.12M
Depreciation & Amortization
281K 369K 389K 425K 838K 1.18M 1.65M 2.1M 2.04M 1.95M 1.5M 1.07M 1.05M 849K 917K 899K 558K 421K